Clinical Trials

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06757634 2026-02-05

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Phase 3 Recruiting

674 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

196 enrolled

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

435 enrolled

Breast Neoplasms

NCT04563507 2025-12-15

Combined Immunotherapies in Metastatic ER+ Breast Cancer

102 enrolled

Breast Neoplasms

NCT06753747 2025-12-03

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

45 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

174 enrolled

Breast Neoplasms

NCT04567420 2025-10-16

DARE

70 enrolled

Breast Neoplasms

NCT05216432 2025-09-22

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

930 enrolled

Breast Neoplasms

NCT03454035 2025-09-11

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

DermatologicGastrointestinal

45 enrolled

Melanoma, Neoplasms, Pancreatic Neoplasms

NCT06947811 2025-06-04

APEAK

71 enrolled

EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor

NCT06113809 2025-06-03

Palbociclib and Pembrolizumab in Sarcoma

Phase EARLY_PHASE1 Recruiting

8 enrolled

Sarcoma

NCT06959979 2025-05-07

Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

60 enrolled

CNS

Medulloblastoma

NCT05432518 2025-04-25

Pilot Trial for Treatment of Recurrent Glioblastoma

Phase EARLY_PHASE1 Recruiting

10 enrolled

CNS

Glioblastoma, Recurrence

NCT06940349 2025-04-23

COPS-01

100 enrolled

Other solid neoplasm

Solid Tumors Refractory to Standard Therapy

NCT06895733 2025-03-26

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

65 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT06856200 2025-03-04

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Phase NA Recruiting

36 enrolled

Advanced HR - Positive, HER2 - Negative Breast Cancer

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

770 enrolled

Rare Tumor

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

300 enrolled

Other solid neoplasm

Solid Tumor

NCT04985266 2024-12-05

TRAK-ER

1,100 enrolled

ER+ Breast Cancer

NCT06478927 2024-06-27

Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib

Phase NA Recruiting

22 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06307249 2024-03-12

PTST_PALBEVA

BreastGastrointestinalGynecologicThoracic

50 enrolled

Breast Neoplasms, Inflammation, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Tumor-Agnostic

Neoplasms

NCT05865132 2023-05-18

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction